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Abstract
Fractional exhaled nitric oxide (FeNO) is a useful tool to diagnose and monitor eosinophilic
bronchial inflammation in asthmatic children and adults. In children younger than 2 years of age
FeNO has been successfully measured both with the tidal breathing and with the single breath
techniques. However, there are a number of methodological issues that need to be addressed in
order to increase the reproducibility of the FeNO measurements within and between infants.
Indeed, a standardized method to measure FeNO in the first 2 years of life would be extremely
useful in order to meaningfully interpret FeNO values in this age group. Several factors related to
the measurement conditions have been found to influence FeNO, such as expiratory flow, ambient
NO and nasal contamination. Furthermore, the exposure to pre- and postnatal risk factors for
respiratory morbidity has been shown to influence FeNO values. Therefore, these factors should
always be assessed and their association with FeNO values in the specific study population should
be evaluated and, eventually, controlled for.
There is evidence consistently suggesting that FeNO is increased in infants with family history of
atopy/atopic diseases and in infants with recurrent wheezing. These findings could support the
hypothesis that eosinophilic bronchial inflammation is present at an early stage in those infants at
increased risk of developing persistent respiratory symptoms and asthma. Furthermore, it has been
shown that FeNO measurements could represent a useful tool to assess bronchial inflammation in
other airways diseases, such as primary ciliary dyskinesia, bronchopulmonary dysplasia and cystic
fibrosis. Further studies are needed in order to improve the reproducibility of the measurements,
and large prospective studies are warranted in order to evaluate whether FeNO values measured
in the first years of life can predict the future development of asthma or other respiratory diseases.
Introduction
Nitric oxide (NO) is formed in biological systems from L-
arginine and oxygen by the enzyme nitric oxide synthases
(NOS), of which 3 isoforms have been described: type I
and III, which are constitutive (cNOS) and type II which
is inducible (iNOS) [1-3] (figure 1). NO is a mediator
with a multitude of important regulatory functions and is
present in exhaled air in humans [4]. The measurement of
nitric oxide in exhaled air (FeNO) is a useful tool to mon-
itor eosinophilic bronchial inflammation in atopic
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asthma [5]. FeNO measurement has been standardized in
cooperative children and adults [6], and normative values
have been published for children aged 4 to 17 years [7].
Guidelines for the measurement of FeNO in young chil-
dren are also available and a number of methodological
issues related to the FeNO measurement in infants have
been addressed [8]. However, to date there is no standard-
ized technique to measure FeNO in the first 2 years of life.
FeNO measurement in infants
A method appropriate for the measurement of FeNO in
infants should be safe, easy to perform and non-invasive.
The tidal breathing and the single breath methods have
been proposed for the measurement of FeNO in infants
and both techniques have showed a good reproducibility
and a high success rate [9-12]. The single breath method
is often combined with other lung function tests, but
requires the sedation of the infant, specialized equipment
and well-trained personnel [9,13]. Therefore, it is less suit-
able for routine testing or large epidemiological studies.
The tidal breathing method has been successfully used
both on-line (FeNO testing with a real-time display of NO
breath profiles) [10] and off-line (collection of exhaled air
into receptacles for delayed analysis) [11] (figure 2). This
is a simple technique that has the advantages of being
non-invasive and can be applied without the use of seda-
tives [14,15]. However, as FeNO is flow-dependent, with
tidal breathing there is a scatter of data depending on the
variation in flow rates [6]. The influence of variable
breathing pattern on FeNO could be limited by correcting
the FeNO values for tidal flow parameters measured dur-
ing the FeNO sampling [16]. Another option would be the
computation of NO output, which takes into account also
expiratory flow (NO output = FeNO × tidal flow). How-
ever, it has been shown that NO output differentiates chil-
dren with and without smoke exposure as well as FeNO
[10], hinting that the correction for expiratory flow might
not be necessary.
The contamination of exhaled air samples with ambient
NO has been shown to occur even for low ambient NO
concentration, particularly with the tidal-breathing
method [15,17]. Hence, it has been suggested that infants
always inhale NO free air prior to the FeNO measurement
[6,15].
In children and adults the nasal mucosa and the paranasal
sinuses are important sources of NO production [6,8].
However, the extent of nasal NO contamination on the
orally exhaled NO in infants is unknown. Although oral
FeNO values are lower than mixed (oral + nasal) FeNO
[11], either nasal or oral NO levels reflect mixed exhaled
NO in infants [17]. The use of a two-compartment face-
mask could reduce nasal contamination, without disturb-
ing the breathing pattern of infants. Nevertheless, the
advantages of excluding the nasal contamination during
the FeNO measurement in infants have still to be shown.
Spirometric maneuvers have been shown to transiently
reduce FeNO levels in asthmatic children [18] and adults
[19] and current guidelines recommend to measure FeNO
prior to lung function testing [6]. The limited data availa-
ble in infants have demonstrate no effect of forced expira-
tory manoeuvres immediately preceding FeNO
measurements on FeNO values in sedated infants with air-
way diseases [11]. Hence, it seems unnecessary to stand-
ardize the sequence of these tests.
Synthesis of nitric oxide (NO) from L-arginine Figure 1
Synthesis of nitric oxide (NO) from L-arginine. iNOS: 
inducible nitric oxide synthases; cNOS: constitutive nitric 
oxide synthases.
Off-line FeNO measurement during tidal breathing Figure 2
Off-line FeNO measurement during tidal breathing. 
Mixed (oral and nasal) expired air is sampled via a face mask, 
connected to an NO-inert balloon via a nonrebreathing 
valve. To reduce contamination by ambient NO, the inspira-
tory port can be connected to a NO-free air reservoir (not 
shown). The measurement should be considered successful if 
the infants maintains a quite tidal breathing during the whole 
procedure, if the facemask is tightly fitted to nose and mouth 
and if at least five tidal breaths are collected.Italian Journal of Pediatrics 2009, 35:21 http://www.ijponline.net/content/35/1/21
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Several foods and beverages, such as nitrate-reach meals
[20] and water consumption [21] have been shown to
transiently influence FeNO. In healthy infants it has been
show that there is no evidence of an effect on FeNO values
of breastfeeding immediately preceding the FeNO meas-
urements [11]. However, such finding should be con-
firmed also in infants with airways diseases.
Factors not related to the measurement conditions, such
as gender, gestational age and anthropometrics have been
associated with FeNO also in infants [16,22]. Therefore,
these factors should always be assessed and a possible
association with FeNO in the specific population under
study should be investigated and, eventually, controlled
for in multivariable analyses. Increased FeNO values have
been found in infants of atopic parents [13]. Also, it has
been shown that infants exposed to maternal smoking
during pregnancy have lower FeNO than unexposed [10],
but this association was subsequently confirmed only in
infants of mothers without atopic disease [16]. These find-
ings suggest that maternal atopy modifies the association
between FeNO and prenatal smoke exposure. A cross-sec-
tional study by Franklin et al. [23] showed that FeNO was
higher in infants exposed to environmental tobacco
smoke after birth than in unexposed, suggesting a direct
irritant effect of smoke on the infants' airways. However,
a prospective birth cohort study recently evaluated the
separate effects of pre- and postnatal tobacco smoke expo-
sure in infants. This study showed that infants continu-
ously exposed to smoke both in utero and after birth had
lower FeNO than never exposed infants and infants
exposed only postnatally, suggesting that the influence of
smoking on FeNO depends on the timing and intensity of
the exposure [16].
Several methodological issues related to the FeNO meas-
urements in infants have been addressed and further stud-
ies in large cohorts of healthy and diseased infants are
needed for standardization.
Results of recent studies support the hypothesis that the
eosinophilic inflammation seen in asthmatic adults may
be present already in wheezy preschool children [24] and
in atopic infants [25]. Therefore, the development of a
non-invasive bed-side test that could help predicting
which infants will develop persistent symptoms would be
of great value.
FeNO and wheezing
Only few studies evaluated FeNO in relation to specific
pulmonary diseases early in life and the majority of them
were performed with a cross-sectional design in selected
populations of infants with a high risk of developing
asthma. Baraldi et al. [14] showed that infants with recur-
rent wheeze had increased FeNO levels during an asthma
exacerbation, which rapidly decreased after a course of
corticosteroid treatment. Other studies have shown high
FeNO levels in infants at increased risk of asthma, such as
infants of atopic parents and infants with recurrent epi-
sodes of wheezing [13,16,17]. Also, in infants with multi-
ple-trigger wheeze, a reduction of FeNO values has been
shown after a course of montelukast or inhaled corticos-
teroid treatment [26-28]. FeNO has been shown to differ-
entiate infants with various airways diseases already in the
first 2 years of life, with the highest levels of FeNO in
infants with recurrent wheezing and with atopic predispo-
sition [29]. Such finding was subsequently replicated by
Moeller et al. [30] who showed that preschoolers with fre-
quent recurrent wheeze and a stringent index for the pre-
diction of asthma at school age had increased FeNO
compared with children with recurrent cough but no his-
tory of wheeze. Overall, these findings suggest that the
eosinophilic bronchial inflammation seen in asthmatic
children and adults could be a characteristic of multiple-
trigger wheezy infants, as recently suggested also by a
bronchial biopsy study [24]. Hence, FeNO might provide
a useful tool to monitor eosinophilic bronchial inflam-
mation early in life. It is noteworthy that previous studies
evaluating the association between FeNO and wheezing
reached similar conclusions, although the method used to
measure FeNO differed between the studies.
Only few prospective studies evaluated the role of FeNO
in the development of wheezing and asthma-like symp-
toms. Latzin et al. [31] showed that a high FeNO after
birth was associated with severe respiratory symptoms in
the first year of life if the mother had an atopic disease or
had been smoking during pregnancy, with the strongest
association when both factors were present. These find-
ings would support the hypothesis that only infants who
are at higher risk of developing asthma, either due to
genetic factors, exposures or both, have higher FeNO. In
fact, in the same study a trend towards a negative associa-
tion between FeNO and severe respiratory symptoms in
infants of nonatopic mothers was found [31]. This is in
agreement with a recent prospective birth cohort study,
which showed that 2 month-old infants with respiratory
symptoms had lower FeNO than asymptomatic infants,
and that these associations were independent and not
modified by maternal atopy [15]. A possible explanation
for the negative association between FeNO and respira-
tory symptoms is that infants participating in these longi-
tudinal studies were not selected because of their health
status and therefore did not represent a population of
infants at increased risk of developing asthma, who would
be more likely to have increased FeNO. Another explana-
tion is that the symptoms assessed in these studies were
grouped in one variable, which included not only wheez-
ing, but also other respiratory symptoms that may be due
to other mechanisms, including infection. Indeed lowItalian Journal of Pediatrics 2009, 35:21 http://www.ijponline.net/content/35/1/21
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FeNO have been found in infants with first time viral-
induced acute wheezy bronchitis [32], suggesting that
acute viral infection may downregulate NO production
[32]. An alternative hypothesis could be that impaired
NO diffusion into the airway leading to reduced FeNO
might be due to epithelial damage and increased airway
secretions in infants with upper respiratory infections
[33]. As episodic wheezing associated to viral infections is
mostly related to neutrophilic airway inflammation [34],
this might explain the reduced FeNO found in infants
with viral-induced wheezing.
The limited follow-up of recent prospective studies does
not allow at the moment to evaluate whether FeNO meas-
ured in the first year of life predicts the development of
asthma at school age. Also, the differences in FeNO values
reported in previous studies comparing infants with and
without symptoms are rather small. Furthermore, it is not
possible to evaluate whether the FeNO values obtained in
infants correlate with the FeNO measured with a stand-
ardized method (on-line or off-line with constant flow) at
school age. As children in these cohort studies will grow
up, a more clear wheezing pattern will become evident
and the diagnosis of asthma will be supported also by the
measurement of lung function. Then, it will be possible to
evaluate with more precision the predictive role of FeNO
measured in infants on the development of asthma at
school age.
FeNO and other pulmonary diseases
FeNO has been explored as a marker of pulmonary dis-
eases that begin early in life, such as primary ciliary dysk-
inesia, bronchopulmonary dysplasia and cystic fibrosis.
Primary ciliary dyskinesia
Primary ciliary dyskinesia (PCD) is an autosomal reces-
sive disease characterized by the lack of effective ciliary
motility, causing abnormal mucociliary clearance. This
leads to recurrent or persistent respiratory infections in
the upper and lower airways [35]. Lower levels of nasal
NO have been found in children with PCD as compared
to children with bronchiectasis, CF, asthma and healthy
controls [36,37]. A recent study has proposed the meas-
urement of nasal NO as a screening test for the diagnosis
of PCD, showing that values above a cut-off level of 105
parts per billion could exclude PCD [38]. Children with
PCD have low FeNO, but overlap in FeNO values between
normal children and those with PCD has been docu-
mented [39]. Therefore, FeNO cannot be used to discrim-
inate patients with PCD from healthy subject as clearly as
measurements of nasal NO [40]. Larger studies are needed
in order to evaluate whether and to what extent FeNO and
nasal NO measurements can be helpful for the screening
or the diagnosis of PCD in the first years of life.
Bronchopulmonary dysplasia and chronic lung disease
Bronchopulmonary dysplasia (BPD) is defined as clinical
signs of respiratory distress, chest radiograph abnormali-
ties, and oxygen dependence at 28 days [41]. BPD
accounts for the majority of chronic lung disease (CLD)
and the airways inflammation of patients with BPD seems
to be mostly mediated by neutrophilic granulocytes [42].
It has been shown that school-age BPD survivors have
lower FeNO than asthmatics with comparable airflow
obstruction, than preterm non-BPD and than healthy
children [43]. It has been hypothesized that the pulmo-
nary damage occurring in the early stage of BPD or the
reduction of the vascular bed [44] could be responsible of
such findings. However, little data is available on the asso-
ciation between FeNO and BPD in the first years of life.
Leipala et al. [45] measured FeNO on-line at constant
flow in 1-year old infants and showed higher FeNO values
in infants with CLD compared to preterm infants without
CLD and to infants born at term. Roiha et al. [46] meas-
ured on-line tidal FeNO in infants at 1 year and showed
that NO output could differentiate between CLD and
non-CLD infants better than FeNO. Also, the current
authors measured FeNO off-line during tidal breathing in
large groups of infants with different airways diseases
below the age of 2 years. BPD infants had higher FeNO
than CF infants, but lower than atopic infants with recur-
rent wheezing, taking lung function parameters, tidal vol-
ume, and breathing frequency into account [29]. Further
studies with longer follow-up are warranted in order to
evaluate whether FeNO can be useful to monitor the
inflammatory pattern of the airways of BPD infants.
Cystic fibrosis
Cystic fibrosis (CF) is a hereditary disease that affects the
lungs, digestive system, sweat glands and male reproduc-
tive organs. CF lung disease is characterized by chronic
neutrophilic airway inflammation, mucus plugging and
bronchial infections with specific bacterial pathogens,
leading to progressive bronchiectasis and lung damage
from which most CF patients die at a median age of 35–
40 years. Low FeNO values have been found in both
adults and children with CF [47,48] and FeNO has also
been shown to correlate with CF severity in children [49].
Although one study previously showed not reduced FeNO
levels in CF patients as compared with healthy infants
[50], there is a large body of evidence suggesting that
infants with CF have lower FeNO values compared with
infants with other respiratory diseases and healthy con-
trols [29,51]. It has been hypothesized that the mecha-
nisms underlying the reduced FeNO values in CF patients
are related to excess secretions in CF airways that might
impair the NO diffusion through the airways [52] or to a
primary defect in NO production [53,54]. A recent study
by Zetterquist et al. [55] supports the latter hypothesis, by
showing that the discrepancy of elevated exhaled NOItalian Journal of Pediatrics 2009, 35:21 http://www.ijponline.net/content/35/1/21
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metabolites and low levels of FeNO are explained by an
impaired function or expression of the enzymes involved
in the NO metabolism. The differences in FeNO values
between CF, healthy infants and infants with other respi-
ratory diseases are relatively small. However, the findings
of lower FeNO in CF patients are consistent between stud-
ies and the data available seem to suggest that FeNO
measurements might be useful in alerting for the diagno-
sis of CF.
Conclusion
Practical recommendations for the measurement of FeNO
in the first 2 years of life have been published, but to date
no standardized technique is available for this age group.
Despite different methods to measure FeNO in infants,
most findings are comparable among study groups and
show consistently high FeNO values in infants at
increased risk of developing asthma. Also, specific pat-
terns of FeNO have been shown for groups of infants with
different airways diseases. Hence, FeNO might provide a
helpful tool for the differential diagnosis of airways dis-
eases in the first years of life. Further follow-up studies in
larger groups of infants are needed in order to assess
whether and to what extent the measurement of FeNO can
predict the subsequent development of airways diseases.
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